🇺🇸 FDA
Patent

US 7550460

2,4-pyrimidinediamine compounds and their uses

granted A61KA61K31/505A61K31/506

Quick answer

US patent 7550460 (2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/505, A61K31/506, A61K31/519, A61K31/5377